Brainstorm Cell Therapeutics (NASDAQ:BCLI) Downgraded to Sell Rating by StockNews.com

Brainstorm Cell Therapeutics (NASDAQ:BCLI) was downgraded by equities researchers at StockNews.com from a “hold” rating to a “sell” rating in a research note issued to investors on Wednesday.

Brainstorm Cell Therapeutics Stock Down 6.3 %

NASDAQ BCLI traded down $0.14 during mid-day trading on Wednesday, hitting $2.09. The stock had a trading volume of 63,331 shares, compared to its average volume of 55,926. The company has a 50 day simple moving average of $1.74 and a 200 day simple moving average of $3.32. The company has a market cap of $11.92 million, a price-to-earnings ratio of -0.44 and a beta of 0.29. Brainstorm Cell Therapeutics has a 52-week low of $1.05 and a 52-week high of $11.89.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Armistice Capital LLC bought a new stake in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm bought 7,917,653 shares of the biotechnology company’s stock, valued at approximately $2,680,000. Armistice Capital LLC owned approximately 11.30% of Brainstorm Cell Therapeutics at the end of the most recent quarter. Institutional investors own 14.33% of the company’s stock.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.